Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy.
about
Fifty years of melphalan use in hematopoietic stem cell transplantationFirst-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies.Molecular Characteristics of High-Dose Melphalan Associated Oral Mucositis in Patients with Multiple Myeloma: A Gene Expression Study on Human MucosaHigh melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation.Anticoagulating obese patients in the modern era.Children's Oncology Group's 2013 blueprint for research: neuroblastoma.Not too little, not too much-just right! (Better ways to give high dose melphalan).Effect of melphalan 140 mg/m(2) vs 200 mg/m(2) on toxicities and outcomes in multiple myeloma patients undergoing single autologous stem cell transplantation-a single center experience.Edentulism and transplant-associated complications in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation.Melflufen - a peptidase-potentiated alkylating agent in clinical trials.Effect of time to infusion of autologous stem cells (24 vs. 48 h) after high-dose melphalan in patients with multiple myeloma.Comparison of 1-day vs 2-day dosing of high-dose melphalan followed by autologous hematopoietic cell transplantation in patients with multiple myeloma.Population Pharmacokinetics and Optimal Sampling Strategy for Model-Based Precision Dosing of Melphalan in Patients Undergoing Hematopoietic Stem Cell Transplantation.Pharmacokinetics and Pharmacodynamics of Treosulfan in Patients With Thalassemia Major Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.Clinical pharmacokinetics of oral drugs in the treatment of multiple myeloma.Melphalan 140mg/m2 or 200mg/m2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party.Associations of High-Dose Melphalan Pharmacokinetics and Outcomes in the Setting of a Randomized Cryotherapy Trial.A case of melphalan sustained accumulation in an 80-year old patient.
P2860
Q26824498-18A822B4-4167-4FF4-BEFE-8739A21867B5Q34501199-9F0B7D16-97DA-47FF-B60E-1B4F9C53F96AQ36239520-59CB0AA4-C4B0-4814-8285-4672C6C19870Q37030719-DBEF8468-4619-4534-B1D1-19497BEBC16EQ37919151-E5EB2FDE-5E40-4834-8FF0-2AF2DE349487Q38068818-7BF865EE-3EB3-484B-AAD4-32A8F811E6BDQ38240941-DB889F18-B674-473E-B20E-3E750A4E2BE2Q38843140-E82D5EA4-CE5A-48B7-A6F5-70348A7E9298Q40113695-E2B3E173-CD54-4B69-8117-F2E9BEA4B175Q42371678-D17BDE13-29FA-4D0E-A4A7-E4F3FCB4D43BQ45285966-6208FA98-1299-46D5-B10A-FBC6C6E46FC9Q46516118-366A36A3-21EE-4871-AAFD-D5E6D3AD89CFQ47972996-FBD2DF80-0526-4FC6-979D-F7B09C54EA7BQ48106141-D6C7CB12-E966-4C13-BEC0-1C74C1409B1DQ48203285-A2633813-1B1B-4220-8EF6-5333429F29E6Q50020987-049EA41C-0643-4832-A144-EFE34AA4EB9DQ50912223-E4C7EF2D-F987-49FD-93CA-00AF0FE0CDE5Q50980877-35D1CF20-D354-428B-99EF-745CC6162231
P2860
Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Population pharmacokinetics of ...... undergoing high dose therapy.
@ast
Population pharmacokinetics of ...... undergoing high dose therapy.
@en
type
label
Population pharmacokinetics of ...... undergoing high dose therapy.
@ast
Population pharmacokinetics of ...... undergoing high dose therapy.
@en
prefLabel
Population pharmacokinetics of ...... undergoing high dose therapy.
@ast
Population pharmacokinetics of ...... undergoing high dose therapy.
@en
P2093
P2860
P50
P1476
Population pharmacokinetics of ...... a undergoing high dose therapy
@en
P2093
Christa E Nath
Douglas Joshua
Gareth Hegarty
Lihua Zeng
Peter J Shaw
Peter Presgrave
Yiu Lam Kwan
P2860
P304
P356
10.1111/J.1365-2125.2010.03638.X
P407
P577
2010-05-01T00:00:00Z